DE4432947C2 - Agent for the treatment of the skin and its use - Google Patents
Agent for the treatment of the skin and its useInfo
- Publication number
- DE4432947C2 DE4432947C2 DE4432947A DE4432947A DE4432947C2 DE 4432947 C2 DE4432947 C2 DE 4432947C2 DE 4432947 A DE4432947 A DE 4432947A DE 4432947 A DE4432947 A DE 4432947A DE 4432947 C2 DE4432947 C2 DE 4432947C2
- Authority
- DE
- Germany
- Prior art keywords
- isoflavone
- composition according
- active ingredient
- skin
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Description
Die vorliegende Erfindung betrifft ein neuartiges Mittel zur Behandlung der Haut, insbesondere zur kosmetischen oder medizinischen Anwendung.The present invention relates to a novel agent for the treatment of Skin, in particular for cosmetic or medical use.
Zur Pflege und Behandlung der Haut werden auf dem Markt zahlreiche Produkte angeboten. Es handelt sich hierbei im wesentlichen um Lotionen, Milche, Cremes und Pasten.For the care and treatment of the skin on the market numerous Products offered. These are essentially lotions, Milk, creams and pastes.
Die angebotenen Reinigungslotionen, -milche, -cremes und -pasten basieren zumeist auf Öl-/Wasseremulsionen mit relativ geringen Gehalten an Fettkomponenten mit reinigenden und pflegenden Zusätzen. Die angebotene breite Palette verschiedener Hautreinigungsprodukte variiert in Zusammensetzung und Gehalt an diversen Wirkstoffen, abgestimmt auf die verschiedenen Hauttypen und spezielle Behandlungsziele.The offered cleaning lotions, -milche, -cremes and pastes are based mostly on oil / water emulsions with relatively low levels of Fat components with cleansing and nourishing additives. The offered wide range of different skin cleansing products varies in Composition and content of various active substances, adjusted to the different skin types and special treatment goals.
Die der Reinigung folgende Hautpflege hat zwei wesentliche Ziele: Zum einen soll sie der Haut die bei der Wäsche unkontrolliert entzogenen Inhaltsstoffe wie Hornzellen, Hautfettlipide, Säurebildner und Wasser zurückführen in den natürlichen Gleichgewichtszustand. Zum anderen sollen sie den natürlichen Alterungsprozeß der Haut sowie den möglichen Schädigungen durch Witterungs- und Umwelteinflüsse weitgehend entgegenwirken. Präparate zur Hautpflege und zum Hautschutz werden in großer Zahl und in vielen Zubereitungsformen angeboten. Die wichtigsten sind Hautcremes, -lotionen, -öle und -gele. Basis der Cremes und Lotionen sind Emulsionen Öl in Wasser oder Wasser in Öl-Form. Die Hauptbestandteile der Öl- bzw. Fett- oder Lipid- Phase sind Fettalkohole, Fettsäuren, Fettsäureester, Wachse, Vaseline, Paraffine sowie weitere Fett- und Ölkomponenten hauptsächlich natürlichen Ursprungs. In der wäßrigen Phase sind neben Wasser hauptsächlich feuchtigkeitsregulierende und feuchtigkeitsbewahrende Substanzen als wesentlicher Hautpflege-Wirkstoff enthalten, ferner konsistenz- bzw. viskositätsregulierende Mittel. Weitere Zusätze wie Konservierungsmittel, Antioxidanzien, Komplexbildner, Parfüm-Öle, Färbemittel sowie spezielle Wirkstoffe werden je nach ihrer Löslichkeit und ihren Stabilitätseigenschaften einer der beiden vorgenannten Phasen beigegeben.The following skin care treatment has two main goals: First It should be the skin the uncontrollably withdrawn during washing ingredients such as Horn cells, skin fat lipids, acidifiers and water are traced back into the natural state of equilibrium. On the other hand, they should be natural Aging process of the skin as well as the possible damage by Weather and environmental influences largely counteract. Preparations for Skin care and skin protection are in great numbers and in many Forms of preparation offered. The most important are skin creams, lotions, oils and gels. The basis of creams and lotions are emulsions oil in water or water in oil form. The main components of the oil or fat or lipid Phase are fatty alcohols, fatty acids, fatty acid esters, waxes, vaseline, Paraffins as well as other fat and oil components mainly natural Origin. In the aqueous phase, water is the main one Moisture-regulating and moisture-retaining substances as contain essential skin care agent, furthermore consistency or viscosity-regulating agents. Other additives such as preservatives, Antioxidants, complexing agents, perfume oils, colorants and special Active ingredients vary depending on their solubility and their stability properties one of the two aforementioned phases added.
Hautöle gehören zu den ältesten Produkten der Hautpflege und werden heute noch verwendet. Basis sind nicht trocknende Pflanzenöle, wie Mandelöl oder Olivenöl mit Zusätzen natürlicher Vitaminöle wie Weizenkeimöl oder Avokadoöl sowie ölige Pflanzenextrakte, z. B. Johanniskraut, Kamille und ähnliche. Der Zusatz von Antioxidanzien gegen Ranzigkeit ist unerläßlich. Gewünschte Duftnoten werden durch Parfüm oder etherische Öle erzielt. Ein Zusatz von Paraffinöl oder flüssigen Fettsäureestern dient zur Optimierung der Anwendungseigenschaften.Skin oils are among the oldest skin care products today still used. Based on non-drying vegetable oils, such as almond oil or Olive oil with additions of natural vitamin oils such as wheat germ oil or avocado oil as well as oily plant extracts, eg. St. John's wort, chamomile and the like. The Addition of antioxidants to rancidity is essential. desired Fragrances are achieved by perfume or essential oils. An addition of Paraffin oil or liquid fatty acid esters are used to optimize the Application properties.
Hautgele sind halbfeste transparente Produkte, die durch entsprechende Gelbildner stabilisiert werden. Man unterscheidet Oleogele, Hydrogele und Öl/Wasser-Gele. Die Typenauswahl richtet sich nach dem gewünschten Anwendungszweck. Die Öl/Wasser-Gele enthalten hohe Emulgator-Anteile und weisen gegenüber Emulsionen gewissen Vorteile auf.Skin gels are semi-solid transparent products by appropriate Gelbildner be stabilized. One distinguishes between oleogels, hydrogels and Oil / water gels. The type selection depends on the desired Application. The oil / water gels contain high levels of emulsifier and have certain advantages over emulsions.
Zu den kosmetischen Mitteln gehören auch die Mittel zur Haarbehandlung. Denn die Haarpflege umfaßt die Reinigung von Kopfhaut und Kopfhaar gleichermaßen. Demzufolge enthalten die Haarwaschmittel besondere hautpflegende Wirkstoffe.Cosmetic products also include hair treatment agents. Because hair care involves the cleansing of the scalp and hair on the head alike. As a result, the shampoos contain special skin care ingredients.
Nachteilig bei den genannten kosmetischen Mitteln ist die Begrenzung der Wirksamkeit.A disadvantage of the mentioned cosmetic products is the limitation of Effectiveness.
In der JP-Anmeldung 82/10775 ist ein isoflavonhaltiges Präparat beschrieben, das den Wirkstoff in Mengen von 0,2% enthält. Die Wirkungen sind auf Durchfeuchtung, Weichmachung und Inhibierung von Melaninbildung ausgerichtet. Derartige Wirkungen sind jedoch nicht das Ziel des erfindungsgemäßen Präparates.In JP application 82/10775 an isoflavone-containing preparation is described which contains the active substance in amounts of 0.2%. The effects are on moisture, Softening and inhibition of melanin formation. Such effects However, they are not the target of the preparation according to the invention.
Die JP-Anmeldung 92/255292 betrifft Isoflavonglycoside. Diese werden ohne bestimmte Mengenangaben als Wirkstoffe verwendet. Das Präparat soll der Verbesserung der Trockenhaut, Alterungsverhinderung und Wachstumsbeschleunigung dienen. Das erfindungsgemäße Präparat zeigt genau die entgegengesetzten Wirkungen, nämlich die Minderung der Fetthaut und eine Wachstumsverzögerung.Japanese Patent Application 92/255292 relates to isoflavone glycosides. These are without certain quantities are used as active ingredients. The drug should be Improvement of dry skin, prevention of aging and Serve growth acceleration. The preparation of the invention shows exactly the opposite effects, namely the reduction of fetal skin and a Growth retardation.
Die JP-Anmeldung 92/200354 betrifft schließlich Isoflavonderivate enthaltende Gemische. Diese dienen der Hautaufhellung und Entzündungsinhibierung. Derartige Wirkungsmechanismen sind nicht Gegenstand der vorliegenden Erfindung.Finally, JP application 92/200354 relates to isoflavone derivatives Mixtures. These are used for skin lightening and inflammation inhibition. such Mechanisms of action are not the subject of the present invention.
Die vorliegende Erfindung hat sich nunmehr die Aufgabe gestellt ein Mittel zur Behandlung der Haut zur Verfügung zu stellen, das für die genannten Anwendungsgebiete einen wirksamen Wirkstoffkomplex aufweist.The present invention has now taken on the task of a means for To provide treatment of the skin, that for the mentioned Areas of application has an active ingredient complex.
Diese Aufgabe wird dadurch gelöst, daß das Mittel als Wirkstoff 0,1 bis 0,005 Gew.-% Isoflavon oder Isoflavonderivate enthält.This object is achieved in that the agent as active ingredient 0.1 to 0.005 wt .-% Isoflavone or isoflavone derivatives.
Bei dem erfindungsgemäßen Isoflavon handelt es sich um die meist zu den Flavonoiden gezählte, gelegentlich auch als Isoflavonoide bezeichnete Gruppe von Stoffen, die sich von 3-Phenyl-4H-1-benzopyran-4-on der folgenden Strukturformel ableiten:In the isoflavone according to the invention are the most to the Flavonoids counted, sometimes referred to as isoflavonoids group of substances that differ from 3-phenyl-4H-1-benzopyran-4-one below Derive structural formula:
Bevorzugt werden erfindungsgemäß 4-Hydroxy-7-Glucose-Isoflavon
(Daidzin), 5,7,4′-Trihydroxy-Isoflavon (Genistein), 5,4′-Dihydroxy-7-Glucose-
Isoflavon (Genistin), 7,4′-Dihydroxy-Isoflavon (Daidzein), 5,7-Dihydroxy-4′-methoxy-
Isoflavon (Biochanin A),
3′,4′,5,7-Tetrahydroxyisoflavon (Orobol), 3′,4′,5-Trihydroxy-7-methoxy
isoflavon (Santal), 3′,5,7-Trihydroxy-4′-methoxyisoflavon (Pratensein),
3′,5,7-Trihydroxy-4′,5′,6-trimethoxyisoflavon (Iridin).According to the invention, preference is given to 4-hydroxy-7-glucose isoflavone (daidzin), 5,7,4'-trihydroxy-isoflavone (genistein), 5,4'-dihydroxy-7-glucose isoflavone (genistin), 7,4 ' Dihydroxy-isoflavone (daidzein), 5,7-dihydroxy-4'-methoxy-isoflavone (biochanin A),
3 ', 4', 5,7-tetrahydroxyisoflavone (Orobol), 3 ', 4', 5-trihydroxy-7-methoxyisoflavone (Santal), 3 ', 5,7-trihydroxy-4'-methoxyisoflavone (pratense), 3 ', 5,7-trihydroxy-4', 5 ', 6-trimethoxyisoflavone (iridine).
Daneben kommen auch die Abkömmlinge des Isoflavons in Betracht, z. B. die in C-2- und C-3-Stellung hydrierten Isoflavone. Ebenso können sämtliche Isoflavonderivate erfindungsgemäß zum Einsatz kommen. Hierzu zählen vor allem Glykoside, Ether, Ester und von den Isoflavonen abgeleitete Säuren.In addition, the descendants of isoflavone into consideration, z. B. the in C-2 and C-3 hydrogenated isoflavones. Likewise, all Isoflavone derivatives are used according to the invention. These include all glycosides, ethers, esters and acids derived from the isoflavones.
Die erfindungsgemäßen Wirkstoffe werden in Konzentrationen von 0,1 bis 0,005 Gew.-% eingesetzt. Hierbei können in dem Mittel zusätzlich Sterole enthalten sein.The active compounds according to the invention are used in concentrations of 0.1 to 0.005 wt .-% used. In addition, sterols may be added to the agent be included.
Aus der jüngsten Literatur ist die medizinische Anwendung von Isoflavonoiden zwar bekannt. Doch handelt es sich hierbei im wesentlichen um Forschungen auf dem Gebiet der Krebsvorsorge. Diese basierten auf der Erkenntnis, daß es in der Tumorrate bei Europäern und Asiaten, insbesondere im Bereich von Prostataerkrankungen und Brustkrebs signifikante Unterschiede gibt. Hierbei war man darauf gestoßen, daß der hohe Anteil an Sojaprodukten in der asiatischen Ernährung eine Ursache zu sein scheint. Im Rahmen der weiteren Arbeiten wurden sodann die Isoflavonoide als Wirkstoffe aus den Sojaprodukten isoliert und auf ihre krebshemmenden Wirkungen hin untersucht.From recent literature is the medical use of isoflavonoids although known. But this is essentially research in the field of cancer screening. These were based on the knowledge that it was in the tumor rate in Europeans and Asians, especially in the area of Prostate and breast cancer are significant differences. in this connection It was discovered that the high proportion of soy products in the Asian diet seems to be a cause. As part of the further Work then became the isoflavonoids as active ingredients from the Sojaprodukten isolated and on their anti-cancer effects examined.
Ein Hinweis auf die erfindungsgemäß überraschend breiten Anwendungsbereiche findet sich jedoch in diesen Forschungsarbeiten nicht. Ebenso war es bei den bisherigen Kosmetika und medizinischen Mitteln zur Behandlung der Haut nicht bekannt, die erfindungsgemäß breite Wirkungspalette unter Einsatz nur eines einzigen Wirkstoffes zu erreichen. Denn das neue Mittel eignet sich zur Minderung der Gefäßneubildung (Couperose), der Behandlung erweiterter Venen (Besenreisern), Akne, Fetthaut, ergrauten Haaren und Pigmentflecken. Insgesamt wirkt das neue Mittel antiproliferativ bei Melanomen, Alopecie, Akne und im Haarbulbus. Darüber hinaus kann mit dem erfindungsgemäßen Mittel der Hautalterung vorgebeugt werden, da Untersuchungen ergeben haben, daß es auch als Radikalfänger wirkt.An indication of the inventively surprisingly wide Areas of application, however, are not found in this research. Likewise it was with the past cosmetics and medical means for Treatment of the skin is not known, the invention wide Range of effects using only a single drug to to reach. Because the new agent is suitable for reducing the Neovascularization (couperose), the treatment of advanced veins (Spider veins), acne, greasy skin, graying hair and pigmentation marks. Overall, the new agent is antiproliferative for melanoma, alopecia, acne and in the hair bulb. In addition, with the agent according to the invention Prevent aging of the skin, since studies have shown that it also acts as a radical scavenger.
Die erfindungsgemäß eingesetzten Isoflavone lassen sich aus Zuckerfraktionen von Pflanzen (Obst, Getreide, Gemüse, Bohnen, Kirschen, Weizen, Hafer, Soja, Erbsen, Linsen, Möhren, Pfirsiche, Kohl, Peranja-Wurzel) oder Mikroorganismen (Pseudomonas) gewinnen. Hierbei können die Isoflavone in reiner Form isoliert werden und direkt als Wirkstoff in das Mittel eingegeben werden.The isoflavones used according to the invention can be prepared Sugar fractions of plants (fruits, cereals, vegetables, beans, cherries, Wheat, oats, soy, peas, lentils, carrots, peaches, cabbage, peranja root) or microorganisms (Pseudomonas). Here, the Isoflavones are isolated in pure form and directly as an active ingredient in the agent be entered.
Ebenso ist es aber auch möglich, Isoflavone synthetisch herzustellen und für die erfindungsgemäßen Zwecke einzusetzen.Likewise, it is also possible to synthetically produce isoflavones and for to use the purposes of the invention.
Schließlich können auch ethanolische, wäßrige Extrakte aus Pflanzen, Mikroorganismen oder synthetischen Gemischen zum Einsatz kommen. Hierbei liegt der Ethanolgehalt vorzugsweise zwischen 100 und 60 Gew.-%.Finally, ethanolic, aqueous extracts of plants, Microorganisms or synthetic mixtures are used. in this connection the ethanol content is preferably between 100 and 60 wt .-%.
Auch ist es denkbar, Hydrolyseprodukte aus Pflanzen oder Mikroorganismen bzw. deren Zuckerfraktionen oder den Extrakten der Pflanzen, Mikroorganismen und Synthesegemische herzustellen.It is also conceivable hydrolysis products of plants or microorganisms or their sugar fractions or the extracts of the plants, Produce microorganisms and synthesis mixtures.
Im folgenden wird die Erfindung unter Bezugnahme auf die Beispiele näher beschrieben.In the following the invention with reference to the examples will be closer described.
Um die Minderung von Blutgefäß-Neubildungen nachzuweisen, wurden die Rezepturen 2 und 3 täglich dreimal auf die entsprechenden Zonen aufgetragen. Ebenso wurde der Einsatz als Radikalfänger und Pigmentflecken- Minderer nachgewiesen. Die Kontrolle nach 8 Wochen ergab jeweils eine leichte Minderung der Blutgefäß-Neubildungen und der Pigmentflecken.To demonstrate the reduction of new blood vessel neoplasms, the Recipes 2 and 3 three times daily to the appropriate zones applied. Likewise, the use as radical scavenger and pigmentation Reduced evidence. The control at 8 weeks yielded one each slight reduction in blood vessel neoplasm and pigmentation.
Die Proliferationsrate-Senkung wurde im Falle von Sebumproduktion Haarwuchs und Hyperkeratinisierung bei Akne geprüft. Dazu wurden die Rezepturen 1 und 2 eingesetzt. Bei der Anwendung der Rezeptur 1 wurde täglich mehrmals auf die entsprechenden Areale mit Hilfe eines handelsüblichen Pumpspray-Fläschchens appliziert; im Falle der Rezeptur 2 wurde dünn auf die entsprechenden Hautareale aufgetragen.The proliferation rate reduction was in case of sebum production Hair growth and hyperkeratinization tested for acne. These were the Recipes 1 and 2 used. When applying the recipe 1 was several times a day to the appropriate areas with the help of a commercially available pump spray vial applied; in the case of recipe 2 was applied thinly to the appropriate skin areas.
Als Ergebnis wurde folgendes festgestellt:
Minderung des Aknegradings nach 15 Tagen und Minderung der Fetthaut nach
4 Wochen. Die Haarwuchsrate konnte erst nach 2 Monaten kontrolliert werden
(Messung des Wuchses in 2 Monaten) und zeigte eine minimale Erniedrigung.As a result, the following was found:
Reduction of the acne grading after 15 days and reduction of the greasy skin after 4 weeks. The hair growth rate could be controlled only after 2 months (measurement of growth in 2 months) and showed a minimal reduction.
Die Grauhaar-Minderung und haarwuchsregulierende Wirkung bei androgenetischer Alopecie wurden mit dem Spray gemäß Rezeptur 5 erprobt. Es wurde nach Monaten eine geringe Ausfallquote bemerkt (Verlängerung der Anagenphase), was den Einfluß auf der Ebene der hormonellen Regulation ohne Hormoneinsatz beweist.The gray hair reduction and hair growth-regulating effect at androgenetic alopecia were tested with the spray according to recipe 5. It was noticed after months a small failure rate (extension of the Anagen phase), which influences the level of hormonal regulation without hormone use proves.
Phase 1 wird bei ca. 60 Grad aufgeschmolzen. Phase 2 wird auf ca. 60 Grad erwärmt.Phase 1 is melted at about 60 degrees. Phase 2 will be at about 60 degrees heated.
Danach werden beide Phasen zusammengegeben und verrührt. Anschließend wird Phase 3 zugegeben und bis zum Gelzustand blasenfrei verrührt. Schließlich wird nach Abkühlung auf ca. 30 Grad Phase 4 zugesetzt.Then both phases are combined and mixed. Subsequently Phase 3 is added and stirred until bubble-free. Finally, after cooling to about 30 degrees, phase 4 is added.
Phase 1 und 2 werden separat auf 70 Grad erwärmt und danach zusammengegeben. Bis zur Abkühlung auf 35 Grad wird gerührt. Schließlich wird Phase 3 unter Rühren zugegeben.Phase 1 and 2 are heated separately to 70 degrees and then combined. Stir until cool to 35 degrees. After all Phase 3 is added with stirring.
Claims (15)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4432947A DE4432947C2 (en) | 1994-09-16 | 1994-09-16 | Agent for the treatment of the skin and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4432947A DE4432947C2 (en) | 1994-09-16 | 1994-09-16 | Agent for the treatment of the skin and its use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE4432947A1 DE4432947A1 (en) | 1996-03-21 |
| DE4432947C2 true DE4432947C2 (en) | 1998-04-09 |
Family
ID=6528338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE4432947A Revoked DE4432947C2 (en) | 1994-09-16 | 1994-09-16 | Agent for the treatment of the skin and its use |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE4432947C2 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19634206C2 (en) * | 1996-08-26 | 2000-01-20 | Ludwig Reinke | Skin care products, in particular for aging skin |
| US7879823B2 (en) | 1999-11-05 | 2011-02-01 | Johnson & Johnson Consumer Companies | Topical anti-cancer compositions and methods of use thereof |
| US7897144B2 (en) | 2001-02-28 | 2011-03-01 | Johnson & Johnson Comsumer Companies, Inc. | Compositions containing legume products |
| US7985404B1 (en) | 1999-07-27 | 2011-07-26 | Johnson & Johnson Consumer Companies, Inc. | Reducing hair growth, hair follicle and hair shaft size and hair pigmentation |
| US8039026B1 (en) | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
| US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
| US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2136233C (en) | 1992-05-19 | 2004-03-30 | Graham Edmund Kelly | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
| AU1793397A (en) † | 1996-03-29 | 1997-10-22 | S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner | Cosmetic or cosmetic preparation for smoothing and tightening the skin in the case of subcutaneous fatty tissue problems, particularly cellulite |
| US5824702A (en) * | 1996-06-07 | 1998-10-20 | Mount Sinai School Of Medicine Of The City University Of New York | Genistein as a preventive against ultraviolet induced skin photodamage and cancer |
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| AU2004224982B2 (en) * | 1996-08-30 | 2007-09-13 | Novogen Research Pty Ltd | Therapeutic methods and compositions involving isoflavones |
| JP2829387B2 (en) * | 1996-09-13 | 1998-11-25 | 農林水産省四国農業試験場長 | Composition for promoting lipolysis in fat cells |
| AU7165798A (en) * | 1997-04-28 | 1998-11-24 | Anticancer, Inc. | Use of genistein and related compounds to treat certain sex hormone related conditions |
| US6146668A (en) | 1997-04-28 | 2000-11-14 | Novogen, Inc. | Preparation of isoflavones from legumes |
| US6060070A (en) * | 1997-06-11 | 2000-05-09 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
| DE19742025A1 (en) * | 1997-09-24 | 1999-03-25 | Beiersdorf Ag | Use of flavone or flavanone derivatives to treat or prevent undesirable skin pigmentation |
| AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
| US5958946A (en) † | 1998-01-20 | 1999-09-28 | Styczynski; Peter | Modulation of hair growth |
| AU2904899A (en) * | 1998-03-16 | 1999-10-11 | Procter & Gamble Company, The | Compositions for regulating skin appearance |
| AUPP260798A0 (en) * | 1998-03-26 | 1998-04-23 | Novogen Research Pty Ltd | Treatment of medical related conditions with isoflavone containing extracts of clover |
| WO2000013661A1 (en) * | 1998-09-10 | 2000-03-16 | Avon Products, Inc. | Method and compositions for reducing dermatological aging and for reducing bruising |
| AUPQ008299A0 (en) | 1999-04-30 | 1999-05-27 | G.J. Consultants Pty Ltd | Isoflavone metabolites |
| AUPQ266199A0 (en) * | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| FR2811562B1 (en) * | 2000-07-13 | 2003-03-07 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, CONTAINING DHEA AND AN ISOFLAVONOID |
| FR2816502B1 (en) * | 2000-11-10 | 2003-04-11 | Oreal | COSMETIC COMPOSITION CONSISTING OF AN AMINOPHENOL DERIVATIVE AND AN ISOFLAVONOIDE |
| FR2818135B1 (en) | 2000-12-15 | 2003-02-14 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, CONTAINING 7-HYDROXY DHEA AND / OR 7-CETO DHEA AND AT LEAST ONE CAROTENOID |
| FR2818148B1 (en) * | 2000-12-15 | 2005-06-24 | Oreal | COMPOSITION, ESPECIALLY COSMETIC, CONTAINING 7-HYDROXY DHEA AND / OR 7-KETO DHEA AND AT LEAST ONE ISOFLAVONOID |
| EP1234572B1 (en) | 2001-02-26 | 2013-10-30 | Mibelle AG Cosmetics | Skin treatment compositions containing isoflavone aglycones |
| AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
| DE10114305A1 (en) * | 2001-03-23 | 2002-09-26 | Beiersdorf Ag | Reducing sebum production using cosmetic or dermatological preparations containing isoflavones, useful for e.g. eliminating comedones or treating greasy hair or dandruff |
| DE10121375B4 (en) * | 2001-05-02 | 2014-01-16 | Beiersdorf Ag | Use of isoflavonoids in cosmetic or dermatological preparations for the prophylaxis and treatment of sensitive skin |
| DE20213787U1 (en) * | 2002-09-04 | 2002-12-19 | Warner Lambert Co | Skin care products |
| DE102005010142A1 (en) * | 2005-03-02 | 2005-11-03 | Dr. Kurt Wolff Gmbh & Co. Kg | Composition for activating hair roots, especially to combat androgenetic alopecia, containing synergistic combination of caffeine and plant extract with phyto-estrogenic action |
| JP5364953B2 (en) * | 2007-08-07 | 2013-12-11 | カルビー株式会社 | New isoflavone compounds |
| FR2974296B1 (en) | 2011-04-19 | 2013-05-24 | Inneov Lab | USE OF A COMBINATION OF A CAROTENOID, A PHYTOESTROGEN AND VITAMIN C AS AN AGENT FOR HYDRATION OF THE SKIN |
| FR2974300B1 (en) | 2011-04-19 | 2013-05-10 | Inneov Lab | USE OF A COMBINATION OF A CAROTENOID, A PHYTOESTROGEN AND VITAMIN C FOR THE PREVENTION AND / OR TREATMENT OF PIGMENT DISORDERS |
-
1994
- 1994-09-16 DE DE4432947A patent/DE4432947C2/en not_active Revoked
Non-Patent Citations (3)
| Title |
|---|
| CA 100:108983 der JP-Anmeldung 82/107775 vom 23. Juni 1982 * |
| CA 111:219115 der JP-Anmeldung 87/255292 vom 9. Oktober 1987 * |
| CA 120:307102 der JP-Anmeldung 92/200354 vom 02. Juli 1992 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19634206C2 (en) * | 1996-08-26 | 2000-01-20 | Ludwig Reinke | Skin care products, in particular for aging skin |
| US8039026B1 (en) | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
| US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
| US7985404B1 (en) | 1999-07-27 | 2011-07-26 | Johnson & Johnson Consumer Companies, Inc. | Reducing hair growth, hair follicle and hair shaft size and hair pigmentation |
| US7879823B2 (en) | 1999-11-05 | 2011-02-01 | Johnson & Johnson Consumer Companies | Topical anti-cancer compositions and methods of use thereof |
| US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
| US7897144B2 (en) | 2001-02-28 | 2011-03-01 | Johnson & Johnson Comsumer Companies, Inc. | Compositions containing legume products |
Also Published As
| Publication number | Publication date |
|---|---|
| DE4432947A1 (en) | 1996-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE4432947C2 (en) | Agent for the treatment of the skin and its use | |
| DE69914726T2 (en) | COMPOSITION FOR REGULATING THE SKIN APPEARANCE | |
| DE60022756T2 (en) | SKIN CARE COMPOSITION | |
| DE19922287B4 (en) | Use of flavonoid esters in cosmetics | |
| DE60022758T2 (en) | SKIN CARE COMPOSITION | |
| DE10035735C2 (en) | Hair tonic to prevent or treat hair loss | |
| DE69913035T9 (en) | Cosmetic composition with antiradical synergistic effect | |
| DE69530926T2 (en) | AGENTS FOR PROMOTING HAIR GROWTH | |
| DE60306565T2 (en) | Anti-cancer compositions for topical use | |
| HU215488B (en) | Method for solubilizing salicylic acid derivatives, cosmetical and/or dermatological compositions containing the solubilized salicylic acid derivatives and use of them | |
| DE19537027A1 (en) | Skin care product for old skin | |
| DE60125823T2 (en) | COMPOSITION, ESPECIALLY COSMETIC COMPOSITION, WITH 7-HYDROXY-DHEA AND / OR 7-KETO-DHEA AND AT LEAST ONE ISOFLAVONOID | |
| DE60035059T2 (en) | MEDIUM TO IMPROVE SKIN TEXTURE | |
| JPH06336419A (en) | External agent for skin | |
| US5565207A (en) | Scalp moisturizer and external skin preparation | |
| EP0966262B1 (en) | Skin care product | |
| WO2022069738A1 (en) | Composition for treating hair, scalp and skin | |
| DE60219432T2 (en) | TOPICAL SOLUTION CONTAINING ISOFLAVON AGLYKON | |
| JPH0745421B2 (en) | Method for preventing discoloration of polyphenol | |
| DE102011057030A1 (en) | Composition containing a tocopherol phosphate, and manufacturing method | |
| JP2007254343A (en) | Cosmetic containing carrot extract | |
| JPH082819B2 (en) | Method for preventing discoloration of polyphenol | |
| DE60105617T2 (en) | Composition and in particular cosmetic composition containing DHEA and / or a precursor or a derivative of DHEA in combination with at least one active against glycation | |
| JP2006008537A (en) | External preparation for skin | |
| DE10114305A1 (en) | Reducing sebum production using cosmetic or dermatological preparations containing isoflavones, useful for e.g. eliminating comedones or treating greasy hair or dandruff |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8363 | Opposition against the patent | ||
| 8331 | Complete revocation |